FOR IMMEDIATE RELEASE
BioStratum Receives patent on Type IV Collagen-Derived Anti-Angiogenesis
Research Triangle Park, N.C., April 21, 1999 -
BioStratum has used the NC1 domain of type IV collagen to develop an anti-tumor agent called Angiocol. In four separate model systems, Angiocol significantly inhibited angiogenesis, the growth of new capillaries from existing blood vessels. Additionally, in three tumor types, Angiocol inhibited tumor growth by as much as 70%.
“Angiocol looks very promising as a non-cytotoxic agent for use in conjunction
with a number of cytotoxic anti-cancer drugs”, said Dr. Archie Prestayko,
President and CEO
The company is currently scaling up the recombinant production of Angiocol for the initiation of human clinical studies anticipated to begin early next year.
Type IV collagen, from which Angiocol is derived, is a principal component of the basal lamina, also known as the basement membrane. The basal lamina is a specialized form of the extracellular matrix that directs cell growth and tissue development through specific binding interactions between neighboring cell receptors and specific domain structures within basal lamina components.
“As we studied the assembly and organization of type IV collagen molecules
to form a functional basal lamina, we discovered that the introduction
of specific domain structures of type IV collagen disrupted the process”,
BioStratum is a privately held company developing proprietary therapeutics
based on recent scientific advances in basal lamina and related technologies.
The company's drug candidates are directed against novel